Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
527.8 CHF | +2.72% | +4.97% | +49.22% |
Apr. 18 | Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix... | |
Apr. 18 | Lonza Finance Launches EUR1 Billion 12-Year Euro Bond | DJ |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 42.69 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+49.22% | 40.57B | A | ||
+1.51% | 42.59B | B | ||
+8.57% | 40.65B | B- | ||
-12.36% | 26.77B | C | ||
+8.92% | 24.81B | B- | ||
-25.13% | 18.17B | B | ||
+29.17% | 12.05B | C+ | ||
-3.12% | 11.7B | C+ | ||
+6.35% | 11.1B | B+ | ||
-16.98% | 9.85B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LONN Stock
- Ratings Lonza Group AG